| pubmed-article:15289864 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C0007102 | lld:lifeskim |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C0282639 | lld:lifeskim |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C0027627 | lld:lifeskim |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C0334227 | lld:lifeskim |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C1257987 | lld:lifeskim |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C1335238 | lld:lifeskim |
| pubmed-article:15289864 | lifeskim:mentions | umls-concept:C0023688 | lld:lifeskim |
| pubmed-article:15289864 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15289864 | pubmed:dateCreated | 2004-8-3 | lld:pubmed |
| pubmed-article:15289864 | pubmed:abstractText | Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands inhibit the growth of PPAR-gamma expressing cancer cells through terminal differentiation. However, there are few studies examining the effect of a PPAR-gamma ligand on metastatic potential of cancer cells in an animal model and the underlying molecular mechanisms. We have recently developed a rectal cancer xenograft animal model in which anti-tumor and anti-metastatic efficacy of agents can be evaluated. This study was designed to examine whether a representative PPAR-gamma ligand, thiazolidinedione (TZD), could inhibit growth and metastasis of PPAR-gamma positive HT-29 human colon cancer cells through the induction of terminal differentiation. TZD caused G1 arrest in association with a marked increase in p21Waf-1, Drg-1, and E-cadherin expression. In untreated cancer cells, fluorescence immunostaining demonstrated beta-catenin in the nucleus and/or cytoplasm; in TZD-treated cancer cells, beta-catenin localization shifted to the plasma membrane, in association with increased E-cadherin at this site and reduced tyrosine phosphorylation of beta-catenin. In addition, TZD completely inhibited lymph node and lung metastases in the xenograft animal model, and TZD inhibited growth of primary xenografts by 40%. These results suggest that TZD can function as a cytostatic anti-cancer agent to inhibit growth and metastasis of HT-29 colon cancer cells through differentiation-promoting effects. These effects involve not only modulation of the E-cadherin/beta-catenin system, but also up-regulation of Drg-1 gene expression. | lld:pubmed |
| pubmed-article:15289864 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15289864 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15289864 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15289864 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:15289864 | pubmed:issn | 1019-6439 | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:NinomiyaItasu... | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:FushidaSachio... | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:FujimuraTakas... | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:ShimizuKoichi... | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:OhtaTetsuoT | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:MiwaKoichiK | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:NishimuraGen-... | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:YiShuangqinS | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:TeradaItsuroI | lld:pubmed |
| pubmed-article:15289864 | pubmed:author | pubmed-author:YoshizumiTets... | lld:pubmed |
| pubmed-article:15289864 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15289864 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:15289864 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15289864 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15289864 | pubmed:pagination | 631-9 | lld:pubmed |
| pubmed-article:15289864 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:meshHeading | pubmed-meshheading:15289864... | lld:pubmed |
| pubmed-article:15289864 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15289864 | pubmed:articleTitle | Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. | lld:pubmed |
| pubmed-article:15289864 | pubmed:affiliation | Department of Surgical Oncology, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-0934, Japan. | lld:pubmed |
| pubmed-article:15289864 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15289864 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15289864 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15289864 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15289864 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15289864 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15289864 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15289864 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15289864 | lld:pubmed |
